samedan logo
 
 
spacer
home > ict > autumn 2017 > perfect planning
PUBLICATIONS
International Clinical Trials

Perfect Planning

The cell and gene therapies being developed today have the potential to cure diseases. To make those treatments possible, another industry has to evolve: logistics. In the past two decades, gene-based clinical trials have increased by almost 500%. The global market for regenerative medicines – including cell therapies, gene/gene-modified cell therapy and tissue engineering – is poised to reach $67 billion in 2020.

While the majority of cell and gene therapies are still experimental – aimed at rare single-gene disorders – researchers hope to build on their successes to develop treatments for multi-gene disorders, including heart disease, hypertension, diabetes, arthritis and Alzheimer’s. This makes the success of clinical trials now vitally important to humanity. However, therein lies the challenge. Unlike traditional medicines, these therapies contain living cells or viral vectors that must be protected to ensure their survival and effectiveness.

Therapies that contain these materials are produced and packaged under strictly controlled conditions. They must be transported around the world and delivered on time at optimum temperature to ensure they arrive in perfect condition. This must be done regardless of weather, traffic, mechanical difficulties, staffing irregularities, customs regulations or processing delays.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lisa Vocat is Global Content Marketing Manager at World Courier, part of AmerisourceBergen’s global specialty logistics business. She is responsible for World Courier’s content marketing strategy and thought leadership development.
spacer
Lisa Vocat
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.1
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement